<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473340</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00131610</org_study_id>
    <nct_id>NCT03473340</nct_id>
  </id_info>
  <brief_title>Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)</brief_title>
  <official_title>A Phase Two Randomized, Double-blinded, Placebo-controlled Study Combining Physiological, Radiographic, and Biological Biomarkers to Study the Anti-fibrotic Effect of Pirfenidone in CLAD Post Lung-transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Greater than 50% of lung transplant recipients show signs of chronic lung allograft&#xD;
      dysfunction (CLAD) by 5 years post-transplantation.Therapies to prevent or slow CLAD are&#xD;
      lacking. Anti-fibrotic therapies may offer an avenue to prevent progression of CLAD and&#xD;
      prolong allograft survival. This study investigates if Pirfenidone therapy will stabilize&#xD;
      lung function decline and slow progression of Functional small airways disease (fSAD) in lung&#xD;
      transplant recipients with CLAD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent of functional small airways disease as measured by parametric response mapping</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>Evaluate if pirfenidone compared to placebo will stabilize progression of fSAD by comparison of inspiratory and expiratory high resolution computed tomography (HRCT) images through co-registration to provide quantitative measures of fSAD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced expiratory volume 1 over 24 weeks (FEV1)</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>Measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced vital capacity (FVC) over 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>Measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse events related to treatment with Pirfenidone</measure>
    <time_frame>28 weeks</time_frame>
    <description>Safety of pirfenidone will be measured by adverse events determined to be related to the study drug through review of medical history, physical exam and laboratory findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment intolerance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subjects permanently discontinuing study medication before 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Disorder Related to Lung Transplantation</condition>
  <condition>Chronic Lung Allograft Dysfunction</condition>
  <arm_group>
    <arm_group_label>Pirfenidone Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Method of Administration: Oral (capsule)&#xD;
Dosing:&#xD;
Days 1 through 7, 267 mg three times daily;&#xD;
Days 8 through 14, 534 mg three times daily;&#xD;
Days 15 through end of treatment (24 weeks), 801 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Method of Administration: Oral (capsule)&#xD;
Dosing:&#xD;
Days 1 through 7, 267 mg three times daily;&#xD;
Days 8 through 14, 534 mg three times daily;&#xD;
Days 15 through end of treatment (24 weeks), 801 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone Capsule</intervention_name>
    <description>Dosing:&#xD;
Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks</description>
    <arm_group_label>Pirfenidone Capsule</arm_group_label>
    <other_name>Esbriet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Dosing:&#xD;
Days 1 through 7, 267 mg three times daily;&#xD;
Days 8 through 14, 534 mg three times daily;&#xD;
Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks</description>
    <arm_group_label>Placebo Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lung transplant recipients 18 years of age or older&#xD;
&#xD;
          -  Greater than 6 months after single or bilateral lung transplantation&#xD;
&#xD;
          -  Baseline FEV1 and FVC values (mean of two highest value measured 3 weeks apart) &gt; 50%&#xD;
             predicted (to assure viable graft)&#xD;
&#xD;
          -  Diagnosis of CLAD (two consecutive spirometric values of FEV1 alone or both FEV1 and&#xD;
             FVC &lt; 80% of baseline)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Acute Rejection (AR) diagnosis by biopsy in the 28 days prior to enrollment&#xD;
&#xD;
          -  Treatment with pulse steroids, Anti-thymocyte Globulin (ATG), extracorporeal&#xD;
             photopheresis (ECP), plasmapheresis, or Immunoglobulin therapy aimed at CLAD within&#xD;
             the 28 days prior to enrollment&#xD;
&#xD;
          -  If the subject is receiving chronic Azithromycin therapy, the dose must be stable for&#xD;
             the 28 days prior to enrollment&#xD;
&#xD;
          -  Presence of active pulmonary infection at the time of enrollment as determined by an&#xD;
             investigator in consultation with the treating pulmonologist&#xD;
&#xD;
          -  Diagnosis of bronchial stenosis either a) requiring stenting, or b) thought to be&#xD;
             responsible for the spirometric decline by principal investigator&#xD;
&#xD;
          -  Abnormal liver function tests (aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) &gt; 2 x upper limit of normal (ULN), Alkaline phosphatase &gt; 2.5 x&#xD;
             ULN, total bilirubin &gt; ULN) or known cirrhosis (&gt;2 times upper limit of normal of&#xD;
             AST/ALT/AP)&#xD;
&#xD;
          -  Total white blood cell (WBC) &lt; 3.0 K/uL&#xD;
&#xD;
          -  Moderate to Severe Renal insufficiency (CrCl &lt;15 mL/min calculated by the&#xD;
             Cockcroft-Gault equation)&#xD;
&#xD;
          -  Use of any medication known to cause significant interactions with pirfenidone (strong&#xD;
             CYP1A2 inhibitors such as Fluvoxamine or Enoxacin or inducers)&#xD;
&#xD;
          -  Pregnancy or lactation. Women of child-bearing potential will have a pregnancy test at&#xD;
             enrollment and must agree to maintain highly effective contraception with two methods&#xD;
             of birth control from the date of consent through the end of the study.&#xD;
&#xD;
          -  Tobacco use within 6 months&#xD;
&#xD;
          -  History of alcohol abuse in the past 1 year as determined by the treating&#xD;
             pulmonologist&#xD;
&#xD;
          -  Any condition other than CLAD that will likely result in death in the next 1 year&#xD;
&#xD;
          -  Any condition in the judgement of the principal investigator that would preclude&#xD;
             participation in this study&#xD;
&#xD;
          -  EKG with QTc interval &gt; 500 msec at screening&#xD;
&#xD;
          -  Listed for repeat lung transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vibha Lama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary J Maliarik, PhD</last_name>
    <phone>734-615-8627</phone>
    <email>marymali@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Mary Maliarik, PhD</last_name>
      <phone>734-615-8627</phone>
      <email>marymali@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Vibha Lama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Vibha Lama</investigator_full_name>
    <investigator_title>Henry Sewall Research Professor of Pulmonary and Critical Care Medicine and Professor of Internal Medicine, Medical School</investigator_title>
  </responsible_party>
  <keyword>CLAD</keyword>
  <keyword>Chronic Rejection</keyword>
  <keyword>Lung Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

